# An Unusual Case of Essential Thrombocythemia and Acute Kidney Injury: Case Report and Literature Review

**Authors:** Celia Rodríguez Tudero, Alberto Martín Arribas, Patricia Antúnez Plaza, José C. De La Flor, Alexandra Lizarazo Suárez, María Pilar Fraile Gómez

PMC · DOI: 10.3390/diseases13050162 · Diseases · 2025-05-21

## TL;DR

A patient with essential thrombocythemia and chronic kidney disease experienced acute kidney injury linked to high platelet counts, which improved with targeted therapy.

## Contribution

This case report adds to the understanding of ET-related kidney complications and the effectiveness of cytoreductive therapy in managing them.

## Key findings

- A 79-year-old patient with ET and CKD developed AKI linked to rising platelet counts.
- Renal biopsy showed lesions consistent with myeloproliferative neoplasm, including ATN and TMA.
- Cytoreductive therapy with hydroxyurea and corticosteroids led to renal improvement and hematologic remission.

## Abstract

Background: Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by the uncontrolled proliferation of megakaryocytes and sustained thrombocytosis. Although its impact on renal function is not well established, a few case reports have described glomerular involvement and associated kidney impairment. Case Report: We present the case of a 79-year-old man with ET and stage 3b/A2 chronic kidney disease (CKD), who was admitted with severe acute kidney injury (AKI). This episode was associated with a progressive rise in platelet count, reaching 1,350,000/μL after discontinuation of anagrelide and loop diuretics. Renal biopsy (RB) revealed structural lesions compatible with a myeloproliferative neoplasm, including acute tubular necrosis (ATN), glomerulomegaly, and thrombotic microangiopathy (TMA). Cytoreductive therapy with hydroxyurea and corticosteroids was initiated, resulting in improvement of renal function and achievement of complete hematologic remission. Discussion: During follow-up, a linear correlation was observed between increasing platelet counts and declining renal function, underscoring the need for dynamic therapeutic adjustment and close monitoring to prevent progression to end-stage renal disease (ESRD). Conclusions: This case highlights the importance of nephrological evaluation in patients with ET and supports the role of cytoreductive therapy in managing ET-associated renal complications.

## Linked entities

- **Chemicals:** anagrelide (PubChem CID 135409400), hydroxyurea (PubChem CID 3657)
- **Diseases:** essential thrombocythemia (MONDO:0005029), acute kidney injury (MONDO:0002492), chronic kidney disease (MONDO:0005300), end-stage renal disease (MONDO:0004375)

## Full-text entities

- **Diseases:** TMA (MESH:D057049), CKD (MESH:D051436), AKI (MESH:D058186), ATN (MESH:D007683), ET (MESH:D013920), ESRD (MESH:D007676), myeloproliferative neoplasm (MESH:D009369), glomerular involvement (MESH:D007674)
- **Chemicals:** anagrelide (MESH:C021139), hydroxyurea (MESH:D006918)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12110408/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12110408/full.md

## References

19 references — full list in the complete paper: https://tomesphere.com/paper/PMC12110408/full.md

---
Source: https://tomesphere.com/paper/PMC12110408